Skip To Main Content
This website contains promotional content and is intended for Healthcare Professionals in the Republic of Ireland only. Adverse event reporting can be found at the bottom of the page
Campus
Campus
Get in Touch

Get in Touch

Toujeo® Insulin Glargine 300U/ml

Toujeo® is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years 7 

Prescribing Infomation can be found through the links in the Product Cards at the bottom of the page

For patients with T1DM or T2DM who need basal insulin, Toujeo® helps provide a balance between effective HBA1c control and risk of hypoglycaemia1-6

  1. Danne T, Matsuhisa M et al. Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: a meta-analysis of 6-month phase 3 clinical trials. Diabetes Obes Metab 2020;22(10):1880-1885
  2. Ritzel R, Roussel R et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 2015;17(9):859-867
  3. Ritzel R, Roussel R et al. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab 2018;20(3):541-548
  4. Battelino T, Bosnyak Z et al. InRange: comparison of the second-generation basal insulin analogues glargine 300 u/ml and degludec 100 u/ml in persons with type 1 diabetes using continuous glucose monitoring-study design. Diabetes Ther 2020;11(4):1017-1027
  5. Battelino T, Danne T et al. Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: the head-to-head randomised controlled InRange trial. Diabetes Obes Metab 2023;25(2):545-555
  6. Rosenstock J, Cheng A et al. More similarities than differences testing insulin glargine 300 units/ml versus insulin degludec 100 units/ml in insulin-naive type 2 diabetes: the randomised head-to-head BRIGHT trial. Diabetes Care 2018;41(10):2147-2154
  7. Toujeo ® Summary of Product Characteristics. Available at: https://www.medicines.ie/medicines/list/all/page-1/per-page-25?query=toujeo   [Accessed: July 2024]

Switching from GLP-1RA to a basal insulin

Download these resources to assist you in starting Toujeo Solostar in a patient currently prescribed a GLP-1RA for whom insulin might be an option.

Medical supervision with close metabolic monitoring is recommended during any switch of therapy or initiation of insulin, and in the initial weeks thereafter.

Start and Switch Guide

Download this summary guide on how to start or switch

Download Guide

Toujeo Features

Learn more Study design
Learn more
Learn more
Learn more

  1. Toujeo® Summary of Product Characteristics. Available at: https://www.medicines.ie/medicines/list/all/page-1/per-page-25?query=toujeo%20. [Accessed July 2024].
  2. Lantus® Summary of Product Characteristics. Available at: https://www.medicines.ie/medicines/list/all/page-1/per-page-25?query=lantus.  [Accessed July 2024].
  3. Tresiba® Summary of Product Characteristics. Available at: https://www.medicines.ie/medicines/list/all/page-1/per-page-25?query=tresiba. [Accessed July 2024].
  4. Levemir® Summary of Product Characteristics. Available at: https://www.medicines.ie/medicines/list/all/page-1/per-page-25?query=levemir.[Accessed July 2024].
  5. Singh R, et al. Eur Endocrinol. 2018;14;47–51
  • ‡5 Pohlmeier H, et al. J Diabetes Sci Technol.2017:11;263-269

Expert Videos

Diabetes Products

Toujeo® Product Page

Click here for Prescribing Information

 

MAT-IE-2300465 (v1.0)
Date of preparation: July 2024

Lantus® Product Page

Click here for Prescribing Information

 

MAT-IE-2300466 (v1.0)
Date of preparation: May 2024

Hypoglycaemia is the most frequent adverse reaction observed in clinical trials conducted with Toujeo®.7 Other common adverse effects are lipohypertrophy and injection site reactions.7

For further information on the safety profile of Toujeo® please consult the Summary of Product Characteristics >

T1DM – Type 1 Diabetes

T2DM – Type 2 Diabetes

MAT-IE-2300465 (v1.0)
Date of Preparation: July 2024